EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Co-delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition of Angiogenesis Against Endometrial Cancer

Shanshan Wang, Jinglin Miao, Ping Zhu, Li Xu

Molecular Biotechnology · 2025

DOI: 10.1007/s12033-024-01227-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biotechnology, 2025. Verfasst von Shanshan Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of the First Obstetrics and Gynecology, Yantai Yuhuangding Hospital, Yantai, 264099, Shandong, China. Hauptthemen laut MEDLINE: Liposomes, Endometrial Neoplasms, Angiogenesis Inhibitors, Bevacizumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, we designed a novel formulation based on liposomes for the co-delivery of cancer-derived exosome inhibitor (ketoconazole, Keto) and angiogenesis inhibitor (bevacizumab, mAb). The designed Combo-Lipo formulation was systematically characterized, exhibiting a uniform average particle size of 100 nm, as well as excellent serum and long-term physical stabilities. The cell viability assay revealed that Combo-Lipo treatment significantly reduced the viability of cancer cells compared to free drugs. Moreover, liposomes effectively inhibited angiogenic mediators and reduced tumor immune suppressive factors. The Combo-Lipo formulation demonstrated potent downregulation of angiogenic factors and synergistic effects in suppressing their production. Furthermore, liposomes inhibited tumor-associated macrophages (TAMs), leading to decreased expression of tumor-promoting factors. Together, these findings highlighted the promising characteristics of Combo-Lipo as a therapeutic formulation, including optimal particle size, serum stability, and potent anti-cancer effects, as well as inhibition of angiogenic mediators and TAMs toward treating endometrial cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiposomesEndometrial NeoplasmsAngiogenesis InhibitorsBevacizumabKetoconazoleNeovascularization, PathologicHumansFemaleCell Line, TumorCell SurvivalAnimalsDrug SynergismMiceParticle SizeMacrophagesAngiogenesis

Stichwörter der Autor:innen

Cancer-associated fibroblastsCo-deliveryEndometrial cancerLiposomesTumor-associated macrophages

Substanzen

LiposomesAngiogenesis InhibitorsBevacizumabKetoconazole

Autor:innen und Institutionen

  • Department of the First Obstetrics and Gynecology, Yantai Yuhuangding Hospital, Yantai, 264099, Shandong, China.
  • Department of the Third Obstetrics and Gynecology, Yantai Yuhuangding Hospital, No. 20 Yuhuangding East Road, Zhifu District, Yantai, 264099, Shandong, China.
  • Department of Reproductive Medicine, Yantai Yuhuangding Hospital, No. 20 Yuhuangding East Road, Zhifu District, Yantai, 264099, Shandong, China. zhuzp111@126.com.
  • Department of the Third Obstetrics and Gynecology, Yantai Yuhuangding Hospital, No. 20 Yuhuangding East Road, Zhifu District, Yantai, 264099, Shandong, China. xuli10011@163.com.

Zitieren

APA

Wang, S., Miao, J., Zhu, P., & Xu, L. (2025). Co-delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition of Angiogenesis Against Endometrial Cancer. Molecular Biotechnology. https://doi.org/10.1007/s12033-024-01227-1

Vancouver

Wang S, Miao J, Zhu P, Xu L. Co-delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition of Angiogenesis Against Endometrial Cancer. Molecular Biotechnology. 2025. doi:10.1007/s12033-024-01227-1

BibTeX
@article{Wang2025,
  author = {Wang, Shanshan and Miao, Jinglin and Zhu, Ping and Xu, Li},
  title = {Co-delivery of Liposomal Ketoconazole and Bevacizumab for Synergistical Inhibition of Angiogenesis Against Endometrial Cancer},
  journal = {Molecular Biotechnology},
  year = {2025},
  doi = {10.1007/s12033-024-01227-1}
}
Kostenlos starten →